Gastroenterology

Positive topline results showed guselkumab (Tremfya) SC induction therapy met all primary and secondary endpoints, suggesting similar clinical benefit to IV induction seen in GALAXI.

The approval is based on data from a pair of phase 3 studies and makes risankizumab-rzaa the first IL-23 specific inhibitor approved for both ulcerative colitis and Crohn’s disease.

The second quarterly issue of 2024 reviews outcomes in liver disease after bariatric surgery, glucagon’s role in esophageal impaction management, and outcomes after cuffitis following pouch creation.

Qazi discusses implications from a recent study exploring the impact of post-IPAA cuffitis on long-term pouch outcomes and the risk of developing strictures and fistulas.

Findings suggest cuffitis after ileal pouch-anal anastomosis is linked to long-term complications including strictures and fistulas, potentially contributing to a greater risk of pouch failure.

Qazi reviews findings from a recent study suggesting glucagon does not have a significant impact on esophageal foreign body impaction resolution.

Findings from a recent randomized controlled trial suggest glucagon does not improve EFBI resolution, time of endoscopy, or extraction length.

Qazi discusses the impact of bariatric surgery on outcomes in patients with decompensated cirrhosis, highlighting its benefit in this patient population.

The retrospective analysis highlights improved outcomes among patients with obesity and a history of bariatric surgery hospitalized with decompensated cirrhosis.

The May 2024 gastroenterology month in review spotlights top research from Digestive Disease Week 2024 and the FDA approval of ColoSense.

Sands reviews key findings from the phase 3 VIVID-1 study of mirikizumab in Crohn’s disease presented at DDW.

Using available literature, the review assesses our current understanding of AATD, emerging biomarkers, and the future of drug development.

Patients with AATD-associated lung disease on augmentation therapy participating in a health management program experienced negligible changes in self-perceived health status.

In honor of World Digestive Health Day, this feature examines the growth of intestinal ultrasound in IBD care in the US and how it aligns with STRIDE-II guidance.

Patients with AATD had increased cardiovascular risk compared to non-AATD COPD and healthy controls, with results suggesting physiological tests may assess risk more accurately.

Lembo describes the potential of a multi-species synbiotic for the treatment of IBS based on findings from an exploratory study he presented at DDW.

Lacy reviews key considerations for the diagnostic evaluation and treatment of abdominal bloating and distension based on his session at DDW.

Singh explains a potential new approach to the low FODMAP diet based on findings from research he presented at DDW suggesting a simplified step-up method.

Krugliak Cleveland explains findings from research she presented at DDW comparing intestinal ultrasound and conventional approaches to disease monitoring in IBD.

Rezaie reviews findings from a prospective clinical trial of a novel palatable elemental diet, highlighting its 100% compliance rate and strong efficacy.

Panaccione explains findings from GALAXI 2 and GALAXI 3 demonstrating guselkumab’s superiority to ustekinumab in Crohn’s disease, presented at DDW.

Joly explains the burden of parenteral support and the significance of new STARS data showcasing apraglutide’s potential in SBS-IF.

A cable-transmission magnetically controlled capsule endoscopy showed comparability to conventional methods in upper GI tract examinations and lesion detection.

Data from PREEMPT CRC reveal the blood-based screening test demonstrated a 79.2% sensitivity for detecting colorectal cancer.

A detailed overview and accompanying quiz on the recommendations made by the AGA in their 2024 guideline on endoscopic eradication